{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:06:30Z","timestamp":1788444390248,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The monthly dapivirine vaginal ring provides partial protection against HIV, and a longer duration ring may reduce user burden and improve adherence. We examined acceptability and preference for 3-month versus 1-month rings for HIV-1 risk reduction in a phase 1 clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In Microbicide Trials Network-036\/International Partnership for Microbicides 047, 49 HIV-negative participants aged 18\u201345 were randomized to one of two 3-month rings or the 1-month ring. Acceptability ratings were collected at enrollment, week 4, and study exit (week 13). At exit, ring preference was assessed quantitatively among all participants and a randomly selected subset of 24 participants completed in-depth interviews. Quantitative and qualitative findings were integrated to explore factors influencing acceptability and preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Acceptability of each ring was initially moderate and increased during the trial. Ratings were lower in the 3-month ring arms than the 1-month arm at each time point, including baseline. Most participants (34\/47; 72%) preferred a 3-month ring at exit; however, this proportion was significantly lower within some subgroups characterized by site, education, race\/ethnicity, and experiences with ring use. Qualitative interviews revealed reservations about hygiene and safety of the 3-month ring, including discomfort with use during menses, but these were usually outweighed by its increased convenience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Both ring durations were highly acceptable at study exit. Although most participants preferred a 3-month ring, preference was more divided in certain subgroups, highlighting the benefit of offering different duration options. Providing additional support to address concerns about hygiene and safety may improve acceptability of a 3-month vaginal ring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2021.0121","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T14:29:15Z","timestamp":1634653755000},"page":"1029-1039","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-9781","authenticated-orcid":false,"given":"Sarah T.","family":"Roberts","sequence":"first","affiliation":[{"name":"Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Hawley","sequence":"additional","affiliation":[{"name":"Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Luecke","sequence":"additional","affiliation":[{"name":"Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mensch","sequence":"additional","affiliation":[{"name":"Population Council, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Wagner","sequence":"additional","affiliation":[{"name":"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hoesley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"McClure","sequence":"additional","affiliation":[{"name":"FHI360, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara P.","family":"Dominguez Islas","sequence":"additional","affiliation":[{"name":"Statistical Center for HIV\/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna M.","family":"Piper","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Y.","family":"Liu","sequence":"additional","affiliation":[{"name":"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, USA."},{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[{"name":"Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, USA."},{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MTN-036\/IPM 047 Protocol Team for the Microbicide Trials Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"UNAIDS data 2020. Geneva Switzerland: UNAIDS 2020."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602046"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30304-0"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30300-3"},{"key":"e_1_3_7_7_2","unstructured":"European Medicines Agency. Dapivirine vaginal ring 25Mg H-W-2168: Summary of product characteristics. Amsterdam The Netherlands: European Medicines Agency 2020."},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25634"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.01.021"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.08.001"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.08.033"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.08.007"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02576-8"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.02.004"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25747"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283590632"},{"key":"e_1_3_7_17_2","first-page":"1","article-title":"Intercoder reliability in qualitative research: Debates and practical guidelines","volume":"19","author":"O'Connor C","year":"2020","unstructured":"O'Connor C, , Joffe H. Intercoder reliability in qualitative research: Debates and practical guidelines. Int J Qual Methods, 2020; 19:1\u201313.","journal-title":"Int J Qual Methods"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000175144.08035.74"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0215-0"},{"key":"e_1_3_7_20_2","first-page":"1","article-title":"The promise of intravaginal rings for prevention: User perceptions of biomechanical properties and implications for prevention product development","volume":"10","author":"Guthrie KM","year":"2015","unstructured":"Guthrie KM, , Vargas S, , Shaw JG, et al. The promise of intravaginal rings for prevention: User perceptions of biomechanical properties and implications for prevention product development. PLoS One, 2015; 10:1\u201317.","journal-title":"PLoS One"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02514-8"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1299-8"},{"key":"e_1_3_7_23_2","unstructured":"Browne EN Mayo AJ Montgomery E et al. Acceptability of and adherence to the dapivirine vaginal ring for HIV-1 prevention. In: 4th International Conference on HIV Treatment and Prevention Adherence Miami Beach FL 2019."},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224898"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0248-4"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02457-0"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002028"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1911-6"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02799-0"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S185712"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001945"},{"key":"e_1_3_7_32_2","doi-asserted-by":"crossref","unstructured":"Montgomery ET Atujuna M Krogstad E et al. The invisible product: Preferences for sustained-release long-acting pre-exposure prophylaxis to HIV among South African youth. 2019; 80:542\u2013550.","DOI":"10.1097\/QAI.0000000000001960"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25528"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02715-1"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17729376"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2283-2"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.15640\/jpbs"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/23294515.2018.1432718"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","unstructured":"Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. In: Smedley BD Stith AY Nelson AR eds. Unequal treatment: Confronting racial and ethnic disparities in health care. Washington (DC): National Acadamies Press 2003. DOI: 10.17226\/12875.","DOI":"10.17226\/12875"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2008.03.019"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147743"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001452"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2021.0121","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2021.0121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2021.0121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:55:14Z","timestamp":1777658114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2021.0121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1089\/jwh.2021.0121"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2021.0121","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}